This allows us to antagonize CCR2 for antitumor purposes, and studies have also confirmed that CCX872, a CCR2 antagonist, increases MS in animal models and further improves MS and OS when used in combination with anti-PD-1 (102). Here, PDCD1 is linked to myeloid sarcoma.